PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects

The treatment of hepatocellular carcinoma (HCC) has witnessed radical changes over the last few years, with the introduction of immune checkpoint inhibitors (ICI) in clinical practice, namely the combination of atezolizumab plus bevacizumab as the standard of care for first-line treatment of advance...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Alessio, Antonio, Rimassa, Lorenza, Cortellini, Alessio, Pinato, David James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352632/
https://www.ncbi.nlm.nih.gov/pubmed/34386437
http://dx.doi.org/10.2147/JHC.S284440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352632/
https://www.ncbi.nlm.nih.gov/pubmed/34386437
http://dx.doi.org/10.2147/JHC.S284440

Ejemplares similares